艾普拉唑联合生长抑素治疗重症急性胰腺炎的效果及安全性分析

doi:10.3969/j.issn.1007-3205.2019.11.005

摘要/Abstract

摘要： ［摘要］
〖HTH〗目的〖HTSS〗〖KG*2〗探讨艾普拉唑联合生长抑素治疗重症急性胰腺炎的有效性、安全性及对氧化应激水平的调节作用。
〖HTH〗方法〖HTSS〗〖KG*2〗纳入符合条件的重症急性胰腺炎患者共98例，按随机数字表法分为对照组和治疗组，每组49例。2组参见《中国急性胰腺炎诊治指南》给予常规干预措施。对照组采用注射用生长抑素治疗。治疗组在对照组基础上给予艾普拉唑肠溶片2片/次，1次/d。2组疗程均为14 d。比较2组症状改善时间。记录2组4周内多器官功能障碍综合征（multi-organ dysfunction syndrome，MODS）、急性呼吸窘迫综合征（acute respiratory distress syndrome，ARDS）的发生率、病死率以及治疗期间不良反应发生情况。检测2组氧化应激指标超氧化物歧化酶（superoxide dismutase，SOD）、丙二醛（malondialdehyde，MDA）、谷胱甘肽过氧化物酶（glutathione peroxidase，GSH-Px）水平。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗组发生率腹胀缓解、腹痛缓解、肠鸣音恢复、肛门排便、体温恢复时间均短于对照组（P＜0.05）。在4周内，治疗组ARDS发生率（12.24%）和MODS发生率（10.2%）均低于对照组（P＜0.05）；2组病死率差异无统计学意义（P＞005）。2组头痛头晕、恶心呕吐、腹泻、皮疹、胸闷发生率差异均无统计学意义（P＞005）。治疗后，治疗组血清SOD、GSH-Px水平明显高于对照组，MDA明显低于对照组（P＜0.05）。
〖HTH〗结论〖HTSS〗〖KG*2〗在基础治疗的同时，应用艾普拉唑联合生长抑素治疗重症急性胰腺炎，可促进症状改善，降低ARDS和MODS 发生率，且安全性好，其疗效可能与抑制氧化应激水平有关。

关键词: 胰腺炎, 急性坏死性, 生长抑素, 艾普拉唑

Abstract: ［Abstract］ Objective〖HTSS〗To investigate the efficacy and safety of Aprazole combined with Somatostatin in treating severe acute pancreatitis and the regulation role of oxidative stress level.
〖HTH〗〖WTHZ〗Methods〖HTSS〗Ninety-eight severe acute pancreatitis patients were selected and randomly divided into treatment group and control group with 49 cases in each group according to the random number table. Both groups received routine therapy referring to “Guidelines for the diagnosis and treatment of acute pancreatitis in China”. Control group was given with Somatostatin. Based on treatment of control group,treatment group was treated with Iprazole enteric-coated tablet(2 tablets/time and qd). Both groups were treated for ten-days. Time of symptoms recovery for both groups were recorded. Rates of multiple organ dysfunction syndrome(MODS) and acute respiratory dysfunction syndrome(ARDS), death rate were recorded for two groups within four weeks after treatment. Adverse reactions were recorded during treatment for two groups. Levels of superoxide dismutase(SOD), malondialdehyde(MDA),and glutathione peroxidase(GSH-Px) were detected for two groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗Time of the recovery of abdominal pain, distention,gurgling sound, defecation and body temperature in treatment group were shorter than control one(P＜0.05). The ARDS and MODS rates of treatment group were 12.24% and 10.2%, wich were evidently lower than control group within four weeks(P＜0.05). There was no statistically significant difference in death rate for two groups(P＞0.05). The incidence of headache, dizziness, nausea and vomiting, diarrhea, rash and chest tightness were not statistically significant between two groups(P＞0.05). After treatment,serum levels of SOD and GSH-Px of treatment group were evidently higher,while MDA was lower,than control group with significant differences(P＜0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗Based on routine therapy, aprazole combined with somatostatin in treating severe acute pancreatitis can promote improvement of symptoms, decrease rates of ARDS and MODS,has good security,and the regulation role of oxidative stress level may be related with the efficacy.

Key words: pancreatitis, acute necrotizing, somatostatin； aprazole

李赛莲，许保，陈正义，黄晓曦，王齐全. 艾普拉唑联合生长抑素治疗重症急性胰腺炎的效果及安全性分析[J]. 河北医科大学学报, doi: 10.3969/j.issn.1007-3205.2019.11.005.

LI Sai-lian, XU Bao, CHEN Zheng-yi, HUANG Xiao-xi, WANG Qi-quan. Efficacy and safety of Aprazole combined with Somatostatin in the treatment of severe acute pancreatitis[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.1007-3205.2019.11.005.

[1]	张涛, 邹萍, 赵琦. 高脂血症胰腺炎患者血清血管紧张素转化酶2与巨噬细胞移动抑制因子水平检测及临床意义 [J]. 河北医科大学学报, 2023, 44(6): 724-728.
[2]	杜军卫, 靳君华. 急性胆源性胰腺炎发病危险因素分析 [J]. 河北医科大学学报, 2023, 44(12): 1448-1452.
[3]	张培建, 刘孟东, 刘科霞, 王雅琪, 刘旭光. 生长抑素联合吲哚美辛栓剂降低胆管癌ERCP术后胰腺炎发生率的效果研究[J]. 河北医科大学学报, 2021, 42(3): 298-303.
[4]	张冰1，朱国玲2*，孙秋1，吉瑞更1. 开滦集团400例急性胰腺炎流行病学及危险因素分析[J]. 河北医科大学学报, 2020, 41(6): 723-727.
[5]	张健，刘贤，郭雅丽，李亚强，徐宝宏*. 甲磺酸加贝酯联合CBP治疗SAP的效果及对炎症“瀑布效应”相关因子的影响[J]. 河北医科大学学报, 2020, 41(3): 272-275,281.
[6]	何晨熙, 朱新影, 赵东强. 《2020国际共识：诊断性超声内镜在慢性胰腺炎管理中的作用》解读[J]. 河北医科大学学报, 2020, 41(12): 1365-1368.
[7]	张培建, 刘孟东, 刘科霞, 王雅琪, 刘旭光. 生长抑素预防ERCP术后高淀粉酶血症及胰腺炎疗效的研究[J]. 河北医科大学学报, 2020, 41(11): 1276-1280.
[8]	米俊, 华鹏, 崔翔, 周荣赛. 免疫增强型肠内营养方案联合微创腹腔引流在重症急性胰腺炎中的临床应用[J]. 河北医科大学学报, 2020, 41(10): 1136-1139,1144.
[9]	纪晨光，赵东强. 《2018国际指南：慢性胰腺炎截面影像学诊断和严重程度评分》解读[J]. 河北医科大学学报, 2019, 40(5): 501-503.
[10]	聂立敏，段〓洁，赵〓瑞，刘艳霞，方艳伟*. 不同冲封管方式对胰腺炎患者留置鼻肠管通畅性的比较研究[J]. 河北医科大学学报, 2019, 40(5): 603-606.
[11]	陈永满，徐渭贤，孙立宝，董金明，赵晓波，周薇莉. 乌司他丁联用生长抑素治疗新生儿消化道畸形术后消化道出血的有效性与安全性评价[J]. 河北医科大学学报, 2017, 37(11): 1292-1294,1299.
[12]	刘云峰 1,高咏梅 2,杨婕琳 2,马琴琴 3,韩树池 1,王俊利 1. 杂合式血液净化序贯治疗重症急性胰腺炎的疗效观察[J]. 河北医科大学学报, 2016, 37(8): 953-956.
[13]	高咏梅1，刘云峰2. 高容量血液滤过联合前列地尔对重症急性胰腺炎血管活性物质的影响及临床疗效[J]. 河北医科大学学报, 2016, 37(6): 697-700.
[14]	李新江，方艳伟，魏浩飞，孙海滨，王川，赵建辉. 细胞间黏附分子1高表达与大鼠SAP早期急性肺损伤的关系[J]. 河北医科大学学报, 2016, 37(4): 392-396.
[15]	王仲健 1,温占红 2,王翠华 2,李红霞 2,王雪蕾 2. 既往高脂血症性胰腺炎伴骨创伤的护理风险管理[J]. 河北医科大学学报, 2016, 37(3): 325-327.

艾普拉唑联合生长抑素治疗重症急性胰腺炎的效果及安全性分析

Efficacy and safety of Aprazole combined with Somatostatin in the treatment of severe acute pancreatitis

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价